Skip to main content
. Author manuscript; available in PMC: 2009 May 1.
Published in final edited form as: Cancer Res. 2008 Jun 1;68(11):4311–4320. doi: 10.1158/0008-5472.CAN-08-0364

Figure 2.

Figure 2

OCICs, under stem cell conditions, are highly resistant to conventional chemotherapies. A, sphere-forming OCICs from tumor T1, under stem cell—selective (black columns) or differentiating (white columns) conditions, were treated with cisplatin (CDDP;30 μmol/L; left), paclitaxel (Ptx;2 μmol/L; center), or cisplatin (30 μmol/L) and paclitaxel (2 μmol/L) for 3 h (CDDP + Ptx; right); cell survival was determined by MTT assays. B, same treatments as in A for OCICs derived from tumor T2, with white columns denoting differentiating conditions and black columns indicating stem cell conditions; *, P < 0.05; **, P < 0.01.